Information Provided By: 
Fly News Breaks for November 26, 2019
AYX
Nov 26, 2019 | 06:15 EDT
Piper Jaffray analyst Brent Bracelin last night initiated coverage of Alteryx with a Neutral rating and $112 price target. The analyst cites "solely" valuation for his rating with the shares up 77% year-to-date. He calls Alteryx a "marquee growth stock" with 15 consecutive quarters of 50%-plus reported growth. However, its growth could moderate in 2020 on tough comparison after 606 tailwinds in 2019, adds the analyst.
News For AYX From the Last 2 Days
AYX
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
